(1) Background: Based on the interactions between immune components in the tumor microenvironment and ovarian cancer (OC) cells, immunotherapies have been demonstrated to be effective in dramatically increasing survival rates. This study aimed to identify landmark genes, construct a prognostic risk model, and explore its relevance to immunotherapy efficacy; (2) Methods: A risk model were built based on the immune- and stromal-related genes, which were extracted from the OC gene expression data of “The Cancer Genome Atlas” (TCGA) database. Survival analysis and receiver operating characteristic (ROC) analysis was then conducted through the model`s riskscore pattern, which was established depending on the TCGA training cohort and verified based on the internally TCGA cohort and externally “Gene Expression Omnibus” (GEO) datasets. Finally, the immune-related characteristics and prognostic values of this model were evaluated; (3) Results: The prognostic risk model of OC exhibited excellent performance in predicting the survival rates in the TCGA and GEO database. This model, significantly associated with 17 functional immune cells, 17 immune checkpoint, PD-1, several immune pathways, may improve immunotherapy efficacy of OC; (4) Conclusions: As a potential prognostic marker, the risk model may offer personalized immunotherapy protocols for OC and provide a theoretical foundation for new immunotherapy combinations.
[Background] To investigate the clinical safety and efficacy of local excision with endovascular gastrointestinal anastomosis stapler (Endo-GIA) in the treatment of T2N0M0 mid-low rectal cancer patients. [Methods] 62 patients admitted with T2N0M0 mid-low rectal cancer in our hospital were collected from January 2015 to December 2018. According to the surgical methods,these patients were divided into local excision group (LE group) and total mesorectal excision group (TME group). 29 patients in the LE group underwent transanal LE with Endo-GIA. 33 patients in the TME group underwent conventional radical surgery according to the principle of TME, including 25 patients receiving Dixon,and 8 patients receiving Miles. Comparative analyses were performed on basic materials, intraoperative and postoperative indicators, and prognosis status between the two groups. [Results] There were no significant differences in BMI, gender, pathological types,tumor size,and tumor distance from the anal verge between LE group and TME group had.Only average age of LE group was higher than that of TME group because several older patients had strong sphincter-preserving willingness and could not tolerate radical surgeries.General characteristics of patients were comparable between the two groups.However, the two groups had significant differences in mean operation time, postoperative hospital stay, intraoperative bleeding volume, and the rate of postoperative complications. The local recurrence rate, mortality rate, overall survival, and 1-year/3-year disease-free survival had no statistical differences between the two groups. [Conclusion] LE combined with Endo-GIA can achieve the same clinical efficacy and safety as TME for patients with T2N0M0 mid-low rectal cancer. LE with Endo-GIA has obvious advantages of less trauma, fewer surgical complications, quicker recovery, and higher living quality over TME.
Background:Ovarian cancer(OC) is the most lethal carcinoma among all gynecological malignancies.Based on the continued understanding of interaction relationships between immune components in tumor microenvironment (TME) and OC cells,immunotherapies have demonstrated to be dramatically effective in increasing survival rates.This research aims to construct a risk model and identify landmark genes which are of vital importance to improve the prognosis of OC. Methods:The gene expression data of 379 OC patients were extracted from The Cancer Genome Atlas(TCGA) database,and immune and stromal related genes were analyzed by difference analysis and weighted correlation network analysis (WGCNA).Subsequently,univariate and multivariate Cox regression analyses were used to build an risk model for OC.Kaplan-Meier survival curves were then taken to depict survival difference between high- and low-risk subgroups.Meanwhile,receiver operating characteristic (ROC) curves and the nomograms were applied to assess the accuracy and validity of the model.Finally,differentiation of immune cells,immune checkpoint molecules,and biological functions between high- and low-risk categories were identified to predict immunotherapy efficacy for OC.Results:GIMAP7,HTRA4,CCL5,ICOS,CD40LG,CD3G,VSIG4,CD2,ANKRD22 were obtained to construct the prognosis risk model;high risk score was an prognosis factor of poor survival rate of OC patients.Further ROC curve and nomogram analyses showed that this model exhibited excellent performance in predicting the 1-,3-,and 5-year survival rate.We obtained 17 functional immune cells,17 immune checkpoint molecules,several immune-related reactions,and GO items which might change the prognosis of OC patients.Conclusions:The 9-genes prognostic model may play critical roles as potential prognostic markers and offer personalized immunotherapy protocols for OC and may provide a theoretical foundation for new immunotherapy combinations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.